Summary
BeiGene, Ltd.'s Q2 2019 report shows a significant increase in total revenues, driven primarily by a substantial collaboration payment of $150 million related to the termination of its tislelizumab agreement with Celgene. While product revenue from in-licensed drugs in China also saw strong year-over-year growth, the company's significant investments in research and development continue to drive substantial operating losses. R&D expenses increased by 39% for the quarter and 49% year-to-date, reflecting pipeline advancement. The company ended the quarter with a solid cash position, but the ongoing high R&D spend indicates a continued need for capital in the future. Investors should monitor the progress of their key drug candidates and the company's ability to manage its significant R&D investments effectively.
Financial Highlights
52 data points| Revenue | $243.35M |
| Cost of Revenue | $17.84M |
| Gross Profit | $225.51M |
| R&D Expenses | $228.76M |
| SG&A Expenses | $82.25M |
| Operating Expenses | $329.18M |
| Operating Income | -$85.83M |
| Net Income | -$85.95M |
| EPS (Basic) | $-0.11 |
| Shares Outstanding (Basic) | 777.51M |
Key Highlights
- 1Total revenues surged by 361% to $243.3 million for the three months ended June 30, 2019, largely due to a $150 million termination payment from Celgene.
- 2Product revenue increased by 85% to $58.1 million for the three months ended June 30, 2019, indicating strong sales growth for in-licensed drugs in China.
- 3Research and development expenses rose by 39% to $228.8 million for the quarter, reflecting continued investment in pipeline advancement.
- 4Net loss attributable to BeiGene, Ltd. decreased by 45% to $85.6 million for the three months ended June 30, 2019, primarily due to the significant collaboration revenue.
- 5Cash, cash equivalents, and short-term investments stood at $1.6 billion as of June 30, 2019, providing a robust liquidity position.
- 6The company regained global rights to its PD-1 inhibitor, tislelizumab, from Celgene following the termination of their collaboration agreement, receiving a $150 million payment in return.
- 7Operating lease accounting standards were adopted, resulting in the recognition of operating lease right-of-use assets and liabilities on the balance sheet.